Dynamics of Clinical Signs of Dry Eye Syndrome of Various Etiologies Against the Background of Drug Therapy Using a Biologically Active Supplement with Antioxidant Action in Various Dosages

The purpose: to study the effectiveness of using different dosages of the anthocyanin-based biologically active supplement “Delfanto”, which has an antioxidant effect, in the complex therapy of patients with dry eye syndrome. The study material consisted of 178 patients (353 eyes) with dry eye syndrome of varying severity, developed on the basis of meibomian blepharitis (109 patients, 215 eyes) and climacteric syndrome (69 patients, 138 eyes), examined in various medical institutions of St. Petersburg, Moscow, Krasnodar, Omsk and Samara. All patients were surveyed using the OSDI questionnaire, the stability of the tear film according to Norn, as well as the amount of total and main tear production according to Schirmer-I and II before the start of the study, as well as on the 3rd, 20th and 30th days of complex therapy. The latter included instillations of artificial tears in combination with oral administration of Delphanto in various dosages: 60 mg for mild to moderate ocular surface xerosis and 120 mg for severe xerosis (stage 1 of the study) and 240 mg for xerosis of all severity (stage 2).

Results. Against the background of complex therapy using Delphanto in various dosages, a progressive decrease in OSDI, an increase in tear film stability, as well as the values of basic and total tear production were noted. In most cases, the values of these parameters were statistically significantly different from their initial values, starting from the 20th day of therapy and reaching a maximum by the 30th day. A dose-dependent effect of Delphanto has been established: in comparison with the results of using Delphanto in a daily dose of 60 mg for mild and moderate forms of xerosis and 120 mg for its severe form, a daily dose of Delphanto in 240 mg was more effective, moreover, in patients with dry eye syndrome due to meibomian blepharitis — to a greater extent for its moderate and severe degree, and in patients with dry eye syndrome due to climacteric syndrome — for its mild clinical form.

Conclusion. The data obtained allow us to recommend the biologically active supplement Delphanto in a dosage of 240 mg in the complex therapy of patients with dry eye syndrome.

1. Brzheskiy VV, Кim GG, Bobryshev VА. Modern possibilities of tear film stability restoration. Russian Journal of Clinical Ophthalmology. 2024;24(3):151–157 (In Russ.). doi: 10.32364/2311-7729-2024-24-3-7.

2. Brzheskiy VV, Golubev SYu, Lebedev OI, Milyudin ES, Apostolova AS, Surov AV, Efimova EL, Varlashina EV, Gorbachevskaya IN, Kirichenko VO. New Opportunities for Complex Therapy in Patients with Dry Eye Syndrome of Various Etiologies. Ophthalmology in Russia. 2020;17(3):481–489 (In Russ.). doi: 10.18008/18165095-2020-3-481-489.

3. Yamashita SI, Suzuki N, Yamamoto K, Iio SI, Yamada T. Effects of MaquiBright® on improving eye dryness and fatigue in humans: A randomized, double-blind, placebo-controlled trial. J Tradit Complement Med. 2018 Nov 22;9(3):172–178. doi: 10.1016/j.jtcme.2018.11.001.

4. Schön C, Wacker R, Micka A, Steudle J, Lang S, Bonnländer B. Bioavailability Study of Maqui Berry Extract in Healthy Subjects. Nutrients. 2018 Nov 9;10(11):1720. doi: 10.3390/nu10111720.

5. Stapleton F, Argüeso P, Asbell P, Azar D, Bosworth C, Chen W, Ciolino J, Craig JP, Gallar J, Galor A, Gomes JAP, Jalbert I, Jie Y, Jones L, Konomi K, Liu Y, MerayoLloves J, Oliveira FR, Quinones VAP, Rocha EM, Sullivan BD, Sullivan DA, Vehof J, Vitale S, Willcox M, Wolffsohn J, Dogru M. TFOS DEWS III Digest Report. Am J Ophthalmol. 2025 Jun 3:S0002-9394(25)00276-4. doi: 10.1016/j.ajo.2025.05.040.

6. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000 May;118(5):615–621. doi: 10.1001/archopht.118.5.615.

7. Norn MS. Dessication of the precorneal film. I. Corneal wetting time. Acta Ophthalmol. (Copenh.). 1969;47:865–880.

8. Schirmer O. Studie zur Physiologie und Pathologie der Tranenabsonderung und Tranenabfuhr. Albrecht v.Graefes Arch. Ophthalmol. 1903; 56(2):197–291.

9. Jones LT. The lacrimal secretory system and its treatment. Amer. J. Ophthalmol. 1966;62(1):47–60.

10. Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki P, Lazreg S, Pult H, Sullivan BD, Tomlinson A, Tong L, Villani E, Yoon KC, Jones L, Craig JP. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017 Jul;15(3):539–574. doi: 10.1016/j.jtos.2017.05.001.

11. Wolffsohn JS, Benítez-Del-Castillo J, Loya-Garcia D, Inomata T, Iyar G, Liang L, Pult H, Sabater AL, Starr CE, Vehof J, Wang MT, Chen W, Craig JP, Dogru M, Quinones VLP, Stapleton F, Sullivan DA, Jones L; TFOS collaborator group. TFOS DEWS III Diagnostic Methodology. Am J Ophthalmol. 2025 May 30:S00029394(25)00275-2. doi: 10.1016/j.ajo.2025.05.033.